Pricing Log in Create free account

Ocular Therapeutix, Inc. (OCUL) vs uniQure N.V. (QURE)

Ocular Therapeutix, Inc. and uniQure N.V. are both Biotechnology companies. Ocular Therapeutix, Inc. and uniQure N.V. are of similar size ($1.5B and $1.4B). uniQure N.V. grew revenue faster over the last twelve months: 28.0% against −8.14%. Ocular Therapeutix, Inc. has the higher net margin (−579.1% vs −1,154.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Ocular Therapeutix, Inc. leads on 11 and uniQure N.V. on 6.

Valuation

Metric OCUL QURE Biotechnology median
P/E n/m n/m 10.60
P/S 28.61 74.94 9.40
P/B 2.86 5.13 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 18.51 44.70 9.02
Earnings yield (21.45%) (16.22%) (32.88%)
Free cash flow yield (17.13%) (12.91%) (23.13%)

Profitability

Metric OCUL QURE Biotechnology median
Gross margin 87.11% 93.85% 68.51%
Operating margin (603.04%) (1,001.74%) 0.00%
Net margin (579.10%) (1,154.84%) 0.00%
Free cash flow margin (490.07%) (956.80%) 0.00%
Return on equity (72.99%) (88.99%) (51.96%)
Return on assets (53.70%) (25.47%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric OCUL QURE Biotechnology median
Revenue growth (TTM) (8.14%) 28.04% 6.76%
EPS growth (last fiscal year) (16.39%) 29.67% 29.88%
Revenue growth, 5-year CAGR 24.45% (15.57%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric OCUL QURE Biotechnology median
Debt to equity 0.14 0.17 0.00
Current ratio 13.11 11.52 4.97
Net debt to EBITDA 2.51 3.36 1.01

Dividend

Metric OCUL QURE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric OCUL QURE Biotechnology median
Market cap 1.41b 1.46b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack